AI drug creation company Absci Corporation (NASDAQ:ABSI) shares are trading higher in premarket on Wednesday after the company entered into a strategic collaboration with Advanced Micro Devices Inc (NASDAQ:AMD) to enhance its AI drug discovery capabilities. The partnership will leverage AMD Instinct accelerators and ROCm software to support Absci’s advanced de novo antibody design models. The deal also includes a $20 million private investment in public equity (PIPE) by AMD, underscoring the ris